Micromet, Inc.

Figuring out how to get a foot in the door with potential big pharma partners is a daunting task for academic researchers and small biotechnology companies. The organizers of the inaugural American As

A Tall Order For The Pace Of M&A December was a red-letter month for biotechnology companies as the large number of acquisitions that were ether completed or announced propelled the NASDAQ Biotech Ind

The NASDAQ Biotech Index is down by nearly 27% since the last peak, the IPO window is virtually shut, there is diminished appetite for secondary offerings, the situation has been made worse by the col

While it is human nature to expect a CEO of a company that has been successful to go on to repeat their triumphs, success may be down to luck or turn out to be elusive in more challenging assignments.